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The p53 protein was discovered many years ago as a 
tumour suppressor gene and despite the wealth of 
information that has accumulated, a complete 
understanding of how p53 functions remains still 
elusive.  
 
p53 is a key regulator of the checkpoint response to 
DNA damage in mammal cells and is affected by loss-
of-function mutations in the majority of human cancer. 
In various normal adult tissues, basal levels of p53 
protein are low, but specific stress signals induce post-
translation modifications and its stabilization, leading to 
activation of distinct transcriptional programmers. In 
response to stress signals p53 mainly acts to repair 
DNA damage and depending on the severity of the 
damage, the cell microenvironment and the cell type, 
p53 can orchestrate different cellular outcomes such as 
apoptosis and senescence.  
 
In addition to its nuclear activity, p53 also possesses 
biological activities that are transcription-independent, 
indeed p53 functions also in the mitochondria and 
cytoplasm, where, depending on the kind of stress either 
triggers apoptosis or inhibits autophagy [1,2]. 
 
Then, the DeltaNp53 isoform, that lacks the 
transactivation domain, contributes to regulate p53 
functions [3]. Notably, the over-expression of 
DeltaNp53 (p44) in mice affects IGF-1 induced gene 
expression and accelerates aging [4]. Cells from these 
mice are more susceptible to both p53-mediated 
apoptosis and senescence, suggesting that enhanced 
tumor suppressive response comes at the cost of 
accelerated aging.  
 
Indeed, emerging evidence suggested that p53 and DNA 
damage checkpoints have also a prominent but still not 
well characterized role in the regulation of aging in 
worm, mice and human [5]. How p53 differentiate 
between different stresses so that its activation leads to 
the correct response and whether aging is part of the 
tumorsuppressive function of p53 are outstanding 
questions. Emerging findings suggest that p53 activity 
on specific target is regulated by specific p53 isoforms, 
in the context of specific activating-signals [3]. 
Typically, p53-dependent growth arrest in G1 phases of  
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the cell cycle have been attributed to transcriptional 
activity of p53 [both activation and repression] but 
contrary to the p53-transcription activation the 
biological significance of p53-mediate transcription 
repression and its role in G2/M arrest of the cell cycle is 
still largely undisclosed. p44/p53 (p47 in human) is an 
N-terminally truncated p53 isoform, which forms 
homo-oligomers and hetero-oligomers with p53, and 
induces G2/M cell-cycle arrest in response to serum 
deprivation or endoplasmic reticulum (ER) stress [6]. 
However, the regulation and physiological role of this 
p44 isoform are just starting to become known and its 
pro-aging function remains the unique indication 
regarding its putative physiological role [4]. Recent 
studies have demonstrated the presence of internal 
ribosome entry site (IRES) sequences in p53 mRNA 
that mediated the translation of both full-length and 
p44/p53 isoforms and represent a novel control of p53 
gene expression and activity [6]. Then, the p44 isoform 
translation was found boosted by ER stress and plays an 
essential role in the unfolded protein response (UPR) 
that leads to a p53-mediated G2 cell cycle arrest [6]. 
Recently, it has been demonstrated that p53-dependent 
G2 arrest following ER stress is mediated by the p44 
isoform [6]. One intriguing open question on p53 role in 
life span determination comes from the assumption that 
the increase of p53 activity is associated at acceleration 
of aging and at decrease of cancer incidence, and in 
opposite way, the attenuation of its activity correlates 
with short life span and increase of incidence of cancer. 
However, contrary to this idea, it appeared that many of 
the long-lived strains models, including p66Shc 
knockout mice [7], attenuation of p53 function does not 
correlated with increased of cancer. Recent findings 
suggest also that p53 and p66Shc are genetically and 
functionally linked [8]. p66Shc is a vertebrate protein 
whose targeted deletion in mice induces resistance to a 
variety of aging-associated diseases, including obesity, 
atherosclerosis, ischemic injury and diabetes, and 
extends lifespan [7]. In mitochondria, p66Shc uses 
reducing equivalents of the electron-transfer chain via 
direct oxidation of cytochrome c to generate pro-
apoptotic reactive oxygen species [ROS], acting as a 
stress-induced red-ox enzyme, that also function as 
signaling molecules to activate specific targets [7]. Our 
group demonstrates that the p53 transcriptional-
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response to oxidative stress involves a large number of 
G2/M-mitosis genes and depends on p66Shc. In 
particular, the expression of p66Shc is indispensable for 
the function of the p53 isoform (p44/p53) to induce of 
G2/M cell cycle arrest, after oxidative stress. 
Consistently, p66Shc deletion decreased some of the 
signs of premature aging observed in mice 
overexpressing the p44 isoform [8], such as, decrease 
lifespan, decrease of fertility, premature accumulation 
of fat tissue in the liver, premature thymic involution 
and alopecia, demonstrating that p66Shc is critical for 
the biological effects of p44/p53 also in vivo [8]. Based 
on these results we hypothesized the tumour 
suppressive and the pro-aging functions of p53 are 
managed by two distinct pathways (Figure 1) and that 
p66Shc is a critical component of the aging pathway. 
This one is triggered by the accumulation of oxidation 
damaged products (mainly proteins) that induces UPR 
and activates a specific p53 pathway that depends on 
the p66Shc redox activity and the p44 short isoform.  
 
As consequence, the existence of two different and not 
redundant p53 pathways explains why the abrogation of 
the p53 aging function, as it occurs in p66Shc null mice, 
does not increase tumour formation. 
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Figure  1.  Distinct  p53  pathways  regulate  tumour  suppression  and  aging.  Oxidative  stress
activates a specific specific transcriptional response, mediated by p66Shc and p44/p53 isoforms,
which regulates cellular senescence and aging.  
